Slate Medicines has emerged with hopes of cracking the code for delivering an injectable novel drug class to prevent migraines, an area where others—such as Eli Lilly and Amgen—have previously failed.
- Home |
- Slate aims to solve migraine injection equation with $130M, asset from China biotech
Slate aims to solve migraine injection equation with $130M, asset from China biotech
- February 23, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
